Dupilumab, a simple pre-filled pen that people inject themselves with every two weeks, is the first biologic that targets both the symptoms of COPD and an underlying cause of the disease. It brings ...

Sanofi and Regeneron’s Dupixent (dupilumab) has received positive final draft guidance from the National Institute for Health ...

Please provide your email address to receive an email when new articles are posted on . Among both women and men with COPD, less than 50% received maintenance inhaler therapy. Less than 70% received ...

Chronic obstructive pulmonary disease (COPD) remains a substantial contributor to morbidity and mortality in the United States with an estimated 3.8% age-adjusted prevalence and 141,733 COPD deaths ...

New global quality standards can help guide health policy change to address the third leading cause of death worldwide.¹ With the COPD mortality rate rising, we desperately need to create a basic ...

A major trial finds the beta blocker bisoprolol neither improves nor worsens outcomes in people with COPD, despite the cardiovascular risk.